211 related articles for article (PubMed ID: 26635033)
1. Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.
de Rooij MF; Kuil A; Kraan W; Kersten MJ; Treon SP; Pals ST; Spaargaren M
Haematologica; 2016 Mar; 101(3):e111-5. PubMed ID: 26635033
[No Abstract] [Full Text] [Related]
2. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
[TBL] [Abstract][Full Text] [Related]
3. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
Cao Y; Yang G; Hunter ZR; Liu X; Xu L; Chen J; Tsakmaklis N; Hatjiharissi E; Kanan S; Davids MS; Castillo JJ; Treon SP
Br J Haematol; 2015 Jul; 170(1):134-8. PubMed ID: 25582069
[No Abstract] [Full Text] [Related]
4. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
[No Abstract] [Full Text] [Related]
7. Waldenstrom macroglobulinemia cells devoid of BTK
Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
[TBL] [Abstract][Full Text] [Related]
8. Future therapeutic options for patients with Waldenström macroglobulinemia.
Castillo JJ; Hunter ZR; Yang G; Argyropoulos K; Palomba ML; Treon SP
Best Pract Res Clin Haematol; 2016 Jun; 29(2):206-215. PubMed ID: 27825467
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
de Rooij MF; Kuil A; Kater AP; Kersten MJ; Pals ST; Spaargaren M
Blood; 2015 Apr; 125(14):2306-9. PubMed ID: 25838279
[No Abstract] [Full Text] [Related]
10.
Gustine JN; Xu L; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Keezer A; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ
Blood Adv; 2019 Oct; 3(19):2800-2803. PubMed ID: 31570491
[No Abstract] [Full Text] [Related]
11. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
12. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
de Rooij MF; Kuil A; Geest CR; Eldering E; Chang BY; Buggy JJ; Pals ST; Spaargaren M
Blood; 2012 Mar; 119(11):2590-4. PubMed ID: 22279054
[TBL] [Abstract][Full Text] [Related]
13. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
Sivina M; Kreitman RJ; Arons E; Ravandi F; Burger JA
Br J Haematol; 2014 Jul; 166(2):177-88. PubMed ID: 24697238
[TBL] [Abstract][Full Text] [Related]
14. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
15. Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia.
Pals ST; Kersten MJ; Spaargaren M
Best Pract Res Clin Haematol; 2016 Jun; 29(2):161-168. PubMed ID: 27825462
[TBL] [Abstract][Full Text] [Related]
16. The importance of the tissue microenvironment in hairy cell leukemia.
Sivina M; Burger JA
Best Pract Res Clin Haematol; 2015 Dec; 28(4):208-16. PubMed ID: 26614899
[TBL] [Abstract][Full Text] [Related]
17. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.
Pepper C; Buggins AG; Jones CH; Walsby EJ; Forconi F; Pratt G; Devereux S; Stevenson FK; Fegan C
Leukemia; 2015 Mar; 29(3):744-7. PubMed ID: 25349153
[No Abstract] [Full Text] [Related]
19. Overcoming mantle cell lymphoma's ibrutinib resistance.
Sinha G
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421347
[No Abstract] [Full Text] [Related]
20. How to Sequence Therapies in Waldenström Macroglobulinemia.
Sarosiek S; Treon SP; Castillo JJ
Curr Treat Options Oncol; 2021 Aug; 22(10):92. PubMed ID: 34426943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
